These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 33573566)
1. Inhibitory Effects of Cathepsin K Inhibitor (ODN-MK-0822) on the Paracrine Pro-Osteoclast Factors of Breast Cancer Cells. Vashum Y; Kottaiswamy A; Bupesh G; Singh RP; Kalaiselvan P; Thiagarajan K; Samuel S Curr Mol Pharmacol; 2021; 14(6):1134-1145. PubMed ID: 33573566 [TBL] [Abstract][Full Text] [Related]
2. Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. Simone V; Ciavarella S; Brunetti O; Savonarola A; Cives M; Tucci M; Opinto G; Maiorano E; Silvestris F BMC Cancer; 2015 Oct; 15():692. PubMed ID: 26468083 [TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of cathepsin K inhibitor (ODN-MK-0822) on invasion, migration and adhesion of human breast cancer cells in vitro. Vashum Y; Premsingh R; Kottaiswamy A; Soma M; Padmanaban A; Kalaiselvan P; Samuel S Mol Biol Rep; 2021 Jan; 48(1):105-116. PubMed ID: 33294960 [TBL] [Abstract][Full Text] [Related]
4. Inhibition of bone resorption by the cathepsin K inhibitor odanacatib is fully reversible. Zhuo Y; Gauthier JY; Black WC; Percival MD; Duong LT Bone; 2014 Oct; 67():269-80. PubMed ID: 25038310 [TBL] [Abstract][Full Text] [Related]
5. The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking. Leung P; Pickarski M; Zhuo Y; Masarachia PJ; Duong LT Bone; 2011 Oct; 49(4):623-35. PubMed ID: 21718816 [TBL] [Abstract][Full Text] [Related]
6. Effects of odanacatib on bone-turnover markers in osteoporotic postmenopausal women: a post hoc analysis of the LOFT study. Duong LT; Clark S; Pickarski M; Giezek H; Cohn D; Massaad R; Stoch SA Osteoporos Int; 2022 Oct; 33(10):2165-2175. PubMed ID: 35711006 [TBL] [Abstract][Full Text] [Related]
7. A Mild Inhibition of Cathepsin K Paradoxically Stimulates the Resorptive Activity of Osteoclasts in Culture. Pirapaharan DC; Søe K; Panwar P; Madsen JS; Bergmann ML; Overgaard M; Brömme D; Delaisse JM Calcif Tissue Int; 2019 Jan; 104(1):92-101. PubMed ID: 30194476 [TBL] [Abstract][Full Text] [Related]
8. Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases. Hao L; Chen J; Zhu Z; Reddy MS; Mountz JD; Chen W; Li YP J Periodontol; 2015 Aug; 86(8):972-83. PubMed ID: 25879791 [TBL] [Abstract][Full Text] [Related]
9. Potential role of odanacatib in the treatment of osteoporosis. Ng KW Clin Interv Aging; 2012; 7():235-47. PubMed ID: 22866001 [TBL] [Abstract][Full Text] [Related]
10. A small molecule, odanacatib, inhibits inflammation and bone loss caused by endodontic disease. Hao L; Chen W; McConnell M; Zhu Z; Li S; Reddy M; Eleazer PD; Wang M; Li YP Infect Immun; 2015 Apr; 83(4):1235-45. PubMed ID: 25583522 [TBL] [Abstract][Full Text] [Related]
11. Knockout and Double Knockout of Cathepsin K and Mmp9 reveals a novel function of Cathepsin K as a regulator of osteoclast gene expression and bone homeostasis. Zhu G; Chen W; Tang CY; McVicar A; Edwards D; Wang J; McConnell M; Yang S; Li Y; Chang Z; Li YP Int J Biol Sci; 2022; 18(14):5522-5538. PubMed ID: 36147479 [TBL] [Abstract][Full Text] [Related]
12. Effects of Long-Term Odanacatib Treatment on Bone Gene Expression in Ovariectomized Adult Rhesus Monkeys: Differentiation From Alendronate. Muise ES; Podtelezhnikov AA; Pickarski M; Loboda A; Tan Y; Hu G; Thomspon JR; Duong le T J Bone Miner Res; 2016 Apr; 31(4):839-51. PubMed ID: 26587671 [TBL] [Abstract][Full Text] [Related]
13. Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. Sims NA; Ng KW Curr Osteoporos Rep; 2014 Mar; 12(1):98-106. PubMed ID: 24477416 [TBL] [Abstract][Full Text] [Related]
14. A novel role for cathepsin K in periosteal osteoclast precursors during fracture repair. Walia B; Lingenheld E; Duong L; Sanjay A; Drissi H Ann N Y Acad Sci; 2018 Mar; 1415(1):57-68. PubMed ID: 29479711 [TBL] [Abstract][Full Text] [Related]
16. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension. Recker R; Dempster D; Langdahl B; Giezek H; Clark S; Ellis G; de Villiers T; Valter I; Zerbini CA; Cohn D; Santora A; Duong LT J Bone Miner Res; 2020 Jul; 35(7):1289-1299. PubMed ID: 32119749 [TBL] [Abstract][Full Text] [Related]
17. Exosomal tumor necrosis factor-α from hepatocellular cancer cells (Huh-7) promote osteoclast differentiation. Li CH; Palanisamy K; Li X; Yu SH; Wang IK; Li CY; Sun KT J Cell Biochem; 2021 Nov; 122(11):1749-1760. PubMed ID: 34383347 [TBL] [Abstract][Full Text] [Related]
18. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity. Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709 [TBL] [Abstract][Full Text] [Related]
19. AP-1 and Mitf interact with NFATc1 to stimulate cathepsin K promoter activity in osteoclast precursors. Pang M; Rodríguez-Gonzalez M; Hernandez M; Recinos CC; Seldeen KL; Troen BR J Cell Biochem; 2019 Aug; 120(8):12382-12392. PubMed ID: 30816596 [TBL] [Abstract][Full Text] [Related]
20. Cathepsin K deficiency promotes alveolar bone regeneration by promoting jaw bone marrow mesenchymal stem cells proliferation and differentiation via glycolysis pathway. Zhang W; Dong Z; Li D; Li B; Liu Y; Zheng X; Liu H; Zhou H; Hu K; Xue Y Cell Prolif; 2021 Jul; 54(7):e13058. PubMed ID: 34053135 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]